Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
44 stopped studies mapped to Cutaneous Melanoma and descendants · 100% state a reason
Over the 44 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04221438 | Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph… | Phase 2 | terminated | Jan 9, 2020 | ECOG-ACRIN Cancer Research Group | Slow accrual | Enrollment / accrual |
| NCT03384836 | Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV… | Phase 1 / Phase 2 | suspended | Dec 27, 2017 | Roswell Park Cancer Institute | interim Analysis | Efficacy / futility |
| NCT06984328 | Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to… | Phase 2 | terminated | May 22, 2025 | Genmab | Genmab has decided to discontinue further clinical development of acasunlimab following strategic… | Safety / toxicity |
| NCT05571839 | A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors | Phase 1 | terminated | Oct 7, 2022 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety concerns. | Safety / toxicity |
| NCT04734704 | Defining the Role of the Skin Microbiome in Immune-related Adverse Events(SKINBIOTA) | N/A | terminated | Feb 2, 2021 | University Hospital, Bordeaux | target number of patients not reached and disabling team changes | Other (stated, no rule matched) |
| NCT04702854 | Evaluation of Ultrasound Biomicroscopy in the Local Staging of Cutaneous Melanoma(BMUMM) | N/A | terminated | Jan 11, 2021 | Centre Hospitalier Universitaire de Nice | recruitment challenges | Enrollment / accrual |
| NCT06391099 | Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With… | N/A | suspended | Apr 30, 2024 | Ohio State University Comprehensive Cancer Center | pending amendment | Other (stated, no rule matched) |
| NCT03699995 | MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma | N/A | terminated | Oct 9, 2018 | OHSU Knight Cancer Institute | The study did not meet its accrual goals due to the departure of study personnel. Study team opted… | Enrollment / accrual |
| NCT03420963 | Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and… | Phase 1 | terminated | Feb 5, 2018 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT03716193 | Measurement of the Partial Pressure of Oxygen in Cutaneous Tumors Using Electron… | N/A | terminated | Oct 23, 2018 | West Virginia University | Terminated March 22, 2022 due to COVID-19 pandemic | COVID-19 / pandemic |
| NCT03325101 | Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma | Phase 1 / Phase 2 | terminated | Oct 30, 2017 | Mayo Clinic | poor accrual | Enrollment / accrual |
| NCT04830124 | Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With…(ARTISTRY-6) | Phase 2 | terminated | Apr 2, 2021 | Mural Oncology, Inc | Study terminated due to business and strategic decision. | Sponsor / business decision |
| NCT05436990 | Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal… | Phase 2 | terminated | Jun 29, 2022 | Yonsei University | According to the protocol criteria, during the Phase 1 analysis, the registered participants'… | Other (stated, no rule matched) |
| NCT05576077 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors(STARLING) | Phase 1 | terminated | Oct 12, 2022 | Turnstone Biologics, Corp. | Sponsor decision | Sponsor / business decision |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | Phase 1 | terminated | Feb 5, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT04375527 | Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or… | Phase 2 | terminated | May 5, 2020 | Jonsson Comprehensive Cancer Center | poor enrollment | Enrollment / accrual |
| NCT02097225 | Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or… | Phase 1 | terminated | Mar 27, 2014 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT05200143 | Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma | Phase 2 | terminated | Jan 20, 2022 | Providence Health & Services | Withdrawn support from BMS. | Other (stated, no rule matched) |
| NCT05050006 | ITIL-168 in Advanced Melanoma(DELTA-1) | Phase 2 | terminated | Sep 20, 2021 | Instil Bio | Business Decision | Sponsor / business decision |
| NCT02978443 | A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab… | Phase 2 | terminated | Dec 1, 2016 | Georgetown University | Lack of Enrollment | Enrollment / accrual |
| NCT03727789 | CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma | Phase 1 | terminated | Nov 1, 2018 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT05482074 | Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 | Phase 2 | withdrawn | Aug 1, 2022 | Dana-Farber Cancer Institute | Principal Investigator left the institute | Investigator |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | Phase 1 | terminated | Jan 28, 2020 | Atreca, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT02748564 | Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | Phase 2 | terminated | Apr 22, 2016 | Rutgers, The State University of New Jersey | Study Complete | Other (stated, no rule matched) |
| NCT04042480 | A Study of SGN-CD228A in Advanced Solid Tumors | Phase 1 | terminated | Aug 2, 2019 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT05219578 | RTX-224 Monotherapy in Patients With Solid Tumors | Phase 1 / Phase 2 | terminated | Feb 2, 2022 | Rubius Therapeutics | The Sponsor terminated study after dosing 2 dose groups (7 pts) and closed trial on 11/30/22.… | Other (stated, no rule matched) |
| NCT05572463 | A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated… | Phase 1 / Phase 2 | withdrawn | Oct 7, 2022 | Innovent Biologics (Suzhou) Co. Ltd. | Sponsor Strategy | Sponsor / business decision |
| NCT01744171 | Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma | Phase 1 | terminated | Dec 6, 2012 | Roswell Park Cancer Institute | Study was Suspended since 2018; PI decided to terminate. | Other (stated, no rule matched) |
| NCT01940809 | Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients… | Phase 1 | terminated | Sep 12, 2013 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT02288897 | PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced… | Phase 3 | terminated | Nov 11, 2014 | Provectus Biopharmaceuticals, Inc. | Inadequate rate of enrollment | Enrollment / accrual |
| NCT02355574 | 5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile…(INTEGRATE) | — | terminated | Feb 4, 2015 | Castle Biosciences Incorporated | Study endpoints completed with lower than anticipated enrollment. Last patient enrolled completed… | Enrollment / accrual |
| NCT02355587 | Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous…(EXPAND) | — | terminated | Feb 4, 2015 | Castle Biosciences Incorporated | Study goals were met with smaller that expected study cohort. Last patient completed the study June… | Other (stated, no rule matched) |
| NCT03425461 | Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating… | Phase 1 | terminated | Feb 7, 2018 | Jonsson Comprehensive Cancer Center | funding | Funding |
| NCT02968680 | Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous… | Phase 1 | terminated | Nov 18, 2016 | University of Southern California | Insufficient accrual | Enrollment / accrual |
| NCT01970527 | Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating… | Phase 2 | terminated | Oct 28, 2013 | University of Washington | Change in standard of care | Other (stated, no rule matched) |
| NCT02587650 | Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS… | Phase 2 | terminated | Oct 27, 2015 | University of California, San Francisco | Funding | Funding |
| NCT01988831 | Efficacy of Propranolol Treatment to Prevent Melanoma Progression | Phase 2 | suspended | Nov 20, 2013 | University Hospital, Geneva | We must delay the study for some financial reasons | Funding |
| NCT02327390 | Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma | Phase 1 | terminated | Dec 30, 2014 | Case Comprehensive Cancer Center | PI Left | Investigator |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic,… | Phase 1 | terminated | Jan 8, 2016 | Mayo Clinic | permanently closed per sponsor's request | Other (stated, no rule matched) |
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced… | Phase 1 / Phase 2 | withdrawn | Oct 31, 2017 | National Cancer Institute (NCI) | The study itself was Disapproved on 04/20/2018 and will not be moving forward. | Other (stated, no rule matched) |
| NCT02812693 | Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With… | Phase 1 / Phase 2 | withdrawn | Jun 24, 2016 | Joanne Jeter | poor accrual | Enrollment / accrual |
| NCT01271907 | Drosophila-generated CTL | Phase 2 | terminated | Jan 7, 2011 | National Cancer Institute (NCI) | Study was terminated due to withdrawal of CRADA partner. | Other (stated, no rule matched) |
| NCT01307618 | Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in… | Phase 2 | terminated | Mar 3, 2011 | National Cancer Institute (NCI) | Due to lack of clinical efficacy and lack of drug supply, trial was closed early and correlative… | Efficacy / futility |
| NCT01120275 | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With… | Phase 2 | terminated | May 10, 2010 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Aug 6, 2026source: clinicaltrials